Efficacy of bevacizumab combined with capecitabine in treatment of advanced colon cancer
Objective To investigate the efficacy of bevacizumab combined with capecitabine in the treatment of advanced colon cancer.Methods A total of 85 patients with advanced colon cancer admitted to the First Affiliated Hospital of Ningbo University from January 2019 to December 2023 were enrolled in this study and divided into the monotherapy group(n=42)and the combination therapy group(n=43)using a random number table method.Patients in the monotherapy group received capecitabine monotherapy after first-line chemotherapy treatment while those in the combination therapy group received bevacizumab combined with capecitabine treatment.The total effective rate of treatment,adverse reactions to treatment,serum carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),Karnofsky Performance Status(KPS)score,and Eastern Cooperative Oncology Group(ECOG)physical status score before and after treatment were recorded and compared between the two groups.Results The total effective rate of the combined drug group was higher than that of the single drug group(88.37%vs 69.05%,χ2=4.753,P<0.05).The incidence of adverse reactions in the combination therapy group was similar to that in the monotherapy group(25.58%vs 28.57%,χ2=0.096,P>0.05).Serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)after treatment in the combination therapy group were(9.50±2.02)ng·mL-1 and(8.94±0.45)U·mL-1,respectively,which were lower than those((15.45±2.68)ng·mL-1 and(9.45±0.23)U·mL-1)in the monotherapy group(t=11.577,6.555,both P<0.05).The KPS and ECOG were(69.73±4.02)and(1.18±0.17)in the combination therapy group,which were better than those of((62.36±3.85)and(1.42±0.20))in the monotherapy group(t=8.629,5.966,both P<0.05).Conclusion The combination of bevacizumab and capecitabine has a significant therapeutic effect on advanced colon cancer.It can decrease serum tumor marker levels and improve physical fitness and quality of life.
Advanced colon cancerCapecitabineBevacizumabSerum tumor markerQuality of lifeAdverse drug reaction
NETL
NSTL
万方数据
